ApprovalTrail

Approval · Notice of Compliance 9093 · 2007

ADDERALL XR: Notice of Compliance 9093

Issued October 16, 2007

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number
9093
Date
October 16, 2007
Company
Shire Canada IncLaval, QC, Canada
Product type
Prescription Pharmaceutical
Submission
New Drug Submission (NDS)
Submission class
Admin
Reason
Manufacturer name change
Therapeutic class
For attention deficit hyperactivity disorder

Products in this notice

BrandDINStatus today
ADDERALL XR02248809Marketed
ADDERALL XR02248810Marketed
ADDERALL XR02248811Marketed
ADDERALL XR02248812Marketed
ADDERALL XR02248813Marketed
ADDERALL XR02248808Marketed

Medicinal ingredients